Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2014.

12 May 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule, Inc. today announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013.

7 May 2014

$RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer$

RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

2 May 2014

Zenalux, RPCI collaborate to enhance Zenascope system to detect oral cancers at an early stage

Zenalux Biomedical, Inc., a leader in biophotonic diagnostics, is working with Roswell Park Cancer Institute to further enhance its flagship Zenascope™ product by adding a high-resolution camera to the system.

25 Apr 2014

RPCI receives FDA approval to enroll patients in phase II clinical trial using I-PDT approach

Roswell Park Cancer Institute (RPCI) has received U.S. Food and Drug Administration (FDA) approval to enroll patients in a phase II clinical trial that will use a unique and highly precise method of delivering interstitial photodynamic therapy (I-PDT) to recurrent tumors of the head and neck.

2 Apr 2014

Scientists identify two markers that predict patient's resistance to radiation therapy for cancer

An international team of researchers, led by Beaumont Health System's Jan Akervall, M.D., Ph.D., looked at biomarkers to determine the effectiveness of radiation treatments for patients with squamous cell cancer of the head and neck.

28 Mar 2014

People urged to undergo oral cancer screenings as part of Oral Cancer Awareness Month

Oral and oropharyngeal cancer (cancer of the mouth and upper throat) collectively kill nearly one person every hour of every day of the year.

27 Mar 2014

Inovio Pharmaceuticals receives three industry awards at World Vaccine Congress

Inovio Pharmaceuticals, Inc. today announced that it was recognized with three industry awards at the World Vaccine Congress, which is being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize outstanding vaccine advancements and achievements of therapeutic and preventive vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders.

26 Mar 2014

Scientist receives $275,000 grant to study human papillomavirus that causes head and neck cancer

Basic scientists focus on understanding how things work, so most don't get the chance to directly impact other people's lives. That's why Michelle Ozbun, PhD, is very excited about her recent grant to study human papillomavirus.

25 Mar 2014

Study: Mood stabilizing drug may help prevent head and neck cancer

A new study indicates that a commonly used mood stabilizing drug may help prevent head and neck cancer. The study is published early online in Cancer, a peer-reviewed journal of the American Cancer Society.

24 Mar 2014

Researchers use "big data" analytics to predict triple-negative breast cancer and other cancers with 95% accuracy

Researchers at Case Western Reserve University and colleagues used "big data" analytics to predict if a patient is suffering from aggressive triple-negative breast cancer, slower-moving cancers or non-cancerous lesions with 95 percent accuracy.

19 Mar 2014

National clinical trial to test new avenue for tinnitus treatment

UT Southwestern Medical Center will take part in a national clinical trial to test a device that could provide relief for people suffering from tinnitus, a persistent buzzing or ringing sound in the ears. The device uses nervous system stimuli to rewire parts of the brain, in hopes of significantly reducing or removing tinnitus.

7 Mar 2014

Avoiding cSMG during radiation therapy is safe in head and neck cancer patients

Avoiding the contralateral submandibular gland during radiation therapy is feasible and safe with advanced stage, node positive head and neck cancers and base of tongue lesions, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

24 Feb 2014

Oropharyngeal cancer patients treated with CRT show decrease in voice and speech quality

Oropharyngeal cancer patients treated with combined chemotherapy and radiation therapy reported a decrease in their voice and speech quality (VSQ) for up to one year after the completion of treatment, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

MATH biomarker with HPV status may provide improved outcomes in HNSCC patients

Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient's HPV status provides an effective indicator of improved patient outcome, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

Humidification of mouth during radiotherapy reduces hospital stay, mucositis in head, neck cancer patients

Patients who received daily humidification of the mouth and throat region beginning from day one of radiation therapy treatment spent nearly 50 percent fewer days in the hospital to manage their side effects, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

HPV-positive oropharyngeal cancer patients show longer survival pattern than those related to smoking

People with late-stage cancer at the back of the mouth or throat that recurs after chemotherapy and radiation treatment are twice as likely to be alive two years later if their cancer is caused by the human papillomavirus (HPV), new research led by a Johns Hopkins scientist suggests.

21 Feb 2014

Reduction of RT to IB lymph nodes may result in better salivary function in head, neck cancer patients

For head and neck cancer patients undergoing radiation therapy, a reduction in the amount of radiation treatment volume to the submandibular (level IB) lymph nodes resulted in better patient-reported salivary function, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

Head and Neck Cancer News and Research

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

Zenalux, RPCI collaborate to enhance Zenascope system to detect oral cancers at an early stage

RPCI receives FDA approval to enroll patients in phase II clinical trial using I-PDT approach

Scientists identify two markers that predict patient's resistance to radiation therapy for cancer

People urged to undergo oral cancer screenings as part of Oral Cancer Awareness Month

Inovio Pharmaceuticals receives three industry awards at World Vaccine Congress

Scientist receives $275,000 grant to study human papillomavirus that causes head and neck cancer

Study: Mood stabilizing drug may help prevent head and neck cancer

Researchers use "big data" analytics to predict triple-negative breast cancer and other cancers with 95% accuracy

National clinical trial to test new avenue for tinnitus treatment

Avoiding cSMG during radiation therapy is safe in head and neck cancer patients

Oropharyngeal cancer patients treated with CRT show decrease in voice and speech quality

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

MATH biomarker with HPV status may provide improved outcomes in HNSCC patients

Humidification of mouth during radiotherapy reduces hospital stay, mucositis in head, neck cancer patients

HPV-positive oropharyngeal cancer patients show longer survival pattern than those related to smoking

Reduction of RT to IB lymph nodes may result in better salivary function in head, neck cancer patients

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News